Sheets Smith Wealth Management Sells 32,020 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

Sheets Smith Wealth Management lowered its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 4.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 633,975 shares of the company’s stock after selling 32,020 shares during the quarter. Sheets Smith Wealth Management’s holdings in ImmunityBio were worth $1,623,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. State Street Corp lifted its stake in ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock valued at $32,195,000 after acquiring an additional 790,408 shares in the last quarter. Barclays PLC grew its position in ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after purchasing an additional 202,248 shares in the last quarter. HighTower Advisors LLC purchased a new stake in ImmunityBio in the 3rd quarter valued at about $136,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after buying an additional 4,545 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of ImmunityBio in the 3rd quarter worth approximately $143,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Stock Up 9.5 %

NASDAQ:IBRX opened at $3.22 on Wednesday. ImmunityBio, Inc. has a 12 month low of $2.28 and a 12 month high of $10.53. The company has a 50 day simple moving average of $3.60 and a two-hundred day simple moving average of $4.15.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Thursday, January 16th. BTIG Research started coverage on ImmunityBio in a research note on Friday, January 10th. They issued a “buy” rating and a $6.00 price target for the company. Finally, EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.